New
BioMarin Pharmaceutical
The AI engine Fit Assessment
BetaThe company will be attending the 2024 Health Tech Forward Event
Blurb
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.
HQ Location
San Rafael (United States)
Founded
1997
Employees
1001 - 5000
Total funding raised
$585.80M
Last Funding Event
Post-IPO Debt, $585.80M, May 11, 2020
Smart insights
- Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
- Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
- 6m headcount growth: 25%
- 1Y headcount growth: 94%
- Headcount-to-last-round ratio: 5.3 employees/$M
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.